Irritable bowel syndrome: New pharmaceutical approaches to treatment

Bailliere's Best Practice in Clinical Gastroenterology

Volumn 13, Issue 3, 1999, Pages 461-471

  Farthing, Michael J G ^a  

^a Digestive Diseases Research Centre   (United Kingdom)

Author keywords

5 HT receptor antagonists; 5 Hydroxytryptamine; Irritable bowel syndrome; Kappa receptor antagonists; Muscarinic M3 receptor antagonists; Therapy

Indexed keywords

ALOSETRON; GRANISETRON; KAPPA OPIATE RECEPTOR AGONIST; MUSCARINIC M3 RECEPTOR ANTAGONIST; ONDANSETRON; PIBOSEROD; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; TEGASEROD; UNCLASSIFIED DRUG; ZAMIFENACIN;

ABDOMINAL PAIN; CENTRAL NERVOUS SYSTEM; DEFECATION; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; REVIEW;

EID: 0033212832     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.1999.0040     Document Type: Article

References (53)

1. Klein KB. Controlled treatment trials in the irritable bowel syndrome: A critique. Gastroenterology 1988; 95: 232-241.
2. Drossman DA, Whitehead WE & Camilleri M. Irritable bowel syndrome: A technical review for practice guideline development. Gastroenterology 1997; 112: 2120-2137.
3. Farthing MJG. New drugs in the management of the irritable bowel syndrome. Drugs 1998; 56: 11-21 .
4. Farthing MJG. Irritable bowel, irritable body, irritable brain? British Medical Journal 1995; 310: 171-175.
5. Manning AP, Thompson WG, Heaton KW et al. Towards positive diagnosis of the irritable bowel. British Medical Journal 1978; 2: 653-654.
6. Thompson WG, Creed F, Drossman DA et al. Functional bowel disease and functional abdominal pain. Gastroenterology International 1992; 5: 75-91.
7. Whorwell PJ, McCallum M, Creed FH et al. Non-colonic features of irritable bowel syndrome. Gut 1986; 27: 37-40.
8. Gomborone JE, Gorard DA, Dewsnap PA et al. Prevalence of irritable bowel syndrome in chronic fatigue. Journal of the Royal College of Physicians 1996; 30: 512-513.
9. Gomborone JE, Dewsnap PA, Libby GW & Farthing MJG. Community study reveals that dysfunctional illness attitudes in irritable bowel syndrome are not wholly a reflection of patient status. Gastroenterology 1993; 104: A513 (Abstract).
10. Gomborone JE, Dewsnap PA, Libby GW et al. Selective affective biasing in recognition memory in the irritable bowel syndrome. Gut 1994; 34: 1230-1234.
11. Gomborone JE, Dewsnap PA, Libby GW & Farthing MJG. Abdominal illness attitudes in irritable bowel syndrome. Journal of Psychosomatic Research 1995; 39: 227-230.
12. Gorard DA & Farthing MJG. Intestinal motor function in irritable bowel syndrome. Digestive Diseases and Sciences 1994; 12: 72-84.
13. Mayer EA & Raybould HE. The role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 1990; 99: 1688-1704.
14. Mayer EA & Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-293.
15. Kendall GPN, Thompson DG, Day SJ et al. Inter and intraindividual variations in pressure volume relations of the rectum in normal subjects and patients with the irritable bowel syndrome. Gut 1990; 31: 1062-1068.
16. Prior A, Maxton DG & Whorwell PJ. Anorectal manometry in irritable bowel syndrome: Differences between diarrhoea and constipation predominant subjects. Gut 1990; 31: 458-462.
17. Cook IJ, van Eeden A & Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987; 93: 727-733.
18. Poynard T, Naveau S, Mory B et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1994; 8: 499-510.
19. Farthing MJG. 5-hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scandinavian Journal of Gastroenterology 1991; 26: 92-100.
20. Bearcroft CP, Perrett D & Farthing MJG. Post-prandial plasma 5-hydroxytryptamine in diarrhoea-predominant irritable bowel syndrome. Gut 1998; 42: 42-46.
21. Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: Clinical implications. Alimentary Pharmacology and Therapeutics 1992; 6: 273-289.
22. 3 receptor subtypes modulate responses to noxious colorectal distension in the rat. Brain Research 1991; 538: 64-75.
23. Foster JM, Houghton LA & Whorwell PJ. Further evidence that sumatriptan induced chest pain is oesophageal in origin: Effect on oesophageal visceral sensation. Gastroenterology 1997; 112: A733 (Abstract).
24. Sanger GJ. 5-hydroxytryptamine and functional bowel disorders. Neurogastroenterology and Motility 1996; 8: 319-331.
25. 3 receptors in small and large intestine. Current Research in Serotonin 1998; 3: 99-104.
26. 4 Receptors in The Brain and Periphery, pp 213-226. Springer-Verlag and RG Landes Co, 1998.
27. Junien JL & Riviere P. The hypersensitive gut - Peripheral kappa agonists as a new pharmacological approach. Alimentary Pharmacology and Therapeutics 1995; 9: 117-126.
28. Dapoigny M, Abitbol H & Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. Digestive Diseases and Sciences 1995; 40: 2244-2248.
29. Liu H, Mantyh PW & Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature, London 1997; 386: 721-724.
30. McQuay HJ & Moore RA. Anti-depressants and chronic pain. British Medical Journal 1997; 314: 763-764.
31. Harrison G. New or old anti-depressants? new is better. British Medical Journal 1994; 309: 763-764.
32. 3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1997; II: 561-568.
33. Maxton DG, Morris J & Whorwell PJ. Selective 5-hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia? Alimentary Pharmacology and Therapeutics 1996; 10: 595-599.
34. 4 antagonism in irritable bowel syndrome (IBS): effect of SB-207266A on rectal sensitivity and small bowel transit. Gut 1997; 4 (supplement 3): A26 (Abstract).
35. 4 receptor antagonist. Journal of Clinical Pharmacology 1997; 37: 229-237.
36. 1 receptor antagonist in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1993; 175-180.
37. 3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1993; 7: 543-551.
38. 3 antagonism (ondansetron). Digestion 1996; 57: 478-483.
39. 3 receptor antagonists in modulation of visceral hypersensitivity. British Journal of Pharmacology 1995; 114: 558-562.
40. Steadman CJ, Talley NJ, Phillips SF & Zinsmeister AR. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome - A pilot study. Mayo Clinic Proceedings 1992; 67: 732-738.
41. 3 receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology 1998; 114: A839 (Abstract).
42. Madrazo I, Franco-Bourland RE, Leon-Maza VM et al. Intra-ventricular somatostatin-14, arginine vasopressin and oxytocin: Analgesic effect in a patient with intractable cancer pain. Applied Neurophysiology 1987; 50: 427-431.
43. Mollenholt P, Post C, Paulsson I et al. Intrathecal and epidural somatostatin in rats: Can anti-nociception, motor effects and neurotoxicity be separated? Pain 1990; 43: 363-370.
44. Penn RD, Paice JA & Kroin JS. Intrathecal octreotide for cancer pain. Lancet 1990; 335: 738 (letter).
45. O'Donnell LJD, Watson AJM, Cameron D et al. Effect of octreotide on mouth-to-caecum transit time in healthy subjects and the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1990; 4: 177-182.
46. Talley NJ, Turner I & Middleton WR. Somatostatin and symptomatic relief of irritable bowel syndrome. Lancet 1987; ii: 1114.
47. Hasler WL, Soudah HC & Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distension. Gastroenterology 1993; 104: 1390-1397.
48. Efskind PS, Bernklev T & Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scandinavian Journal of Gastroenterology 1996; 31: 463-468.
49. Gorard DA, Libby GW & Farthing MJG. Effect of a tricyclic anti-depressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Digestive Diseases and Sciences 1995; 40: 86-95.
50. Schutze K. Brandstatter G, Dragosics B et al. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1997; 11: 387-394.
51. Farup PG, Hovdenak N, Wetterhus S et al. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scandinavian Journal of Gastroenterology 1998; 33: 128-131.
52. 4 agonist (HFT919) improves symptoms in constipation predominant irritable bowel syndrome (C-IBS). Digestion 1998; 59 (supplement 3): 735.
53. Gorard DA, Libby GW & Farthing MJG. 5-hydroxytryptamine and human small intestinal motility: Effect of inhibiting 5-hydroxytryptamine uptake. Gut 1994; 34: 496-500.